Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: A randomised open-label parallel group four months comparison in patients with type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 114, Issue 9, 2006, Pages 511-519

  Ligthelm, Robert J ^a   Mouritzen, U ^b   Lynggaard, H ^b   Landin Olsson, M ^c   Fox, C ^d   Le Devehat, C ^e   Romero, E ^f   Liebl, A ^g  

^a Havenziekenhuis   (Netherlands)

^b NOVO NORDISK A S   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e Hôpital Pierre Bérégovoy   (France)

^f UNIVERSITY OF VALLADOLID   (Spain)

^g Diabeteszentrum ^*  (Germany)

Author keywords

Basal bolus regimen; Glycaemic control MS: Biphasic insulin aspart; Insulin; Insulin aspart; NovoMix 50; NovoMix 70 NovoMix30; Premixed insulin analogues; Thrice daily insulin regimen; Type 2 diabetes

Indexed keywords

BIPHASIC INSULIN; GLUCOSE; INSULIN ASPART; ISOPHANE INSULIN;

ADULT; AGED; ARTICLE; BODY MASS; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS;

AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33845309408     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-924424     Document Type: Article

References (28)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28: S4-S36
2. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399
3. Boehm BO, Vaz JA, Brondsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004; 15: 496-502
4. Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999; 35: 307-335
5. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 1988; 37: 736-744
6. Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, Schaupp L, Krejs GJ, Pieber TR. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000; 17: 371-375
7. Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 446-454
8. Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the "natural history" of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract 1994; 26: 177-187
9. Ejskjaer N, Rasmussen M, Kamp N, Lindholm A, Christiansen JS. Comparison of thrice daily "high" vs. "medium" premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 438-445
10. Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BH, Koelendorf K, Friberg HH, Windfeld K, Lindholm A. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004; 21: 769-775
11. Home PD. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabetic Medicine 2000; 17: 762
12. International Conference on Harmonisation (ICH). Topic E 6. Harmonised Tripartite Guideline for Good Clinical Practice. Step 5, Consolidated Guideline. 1-5 1996
13. Jain R, Allen E, Wahl T, Wahlen J, Bressler P, Deng L, Garber A. Efficacy of biphasic insulin aspart 70/30 in patients with T2DM not achieving glycemic targets on OADs with/without basal insulin therapy. Abstract submitted for presentation at American Diabetes Association (ADA) 10-14 June, San Diego, California, 2005
14. Jain R, Wahl T, Wahlen J, Bressler P, Hu P, Allen E. Patients with type 2 diabetes can achieve A1C targets with once-daily biphasic insulin aspart 70/30 before supper. Diabetes 2004; 53: A130
15. Kann P, Toft A. Twice daily biphasic insulin aspart 30 plus metformin compared with once-daily insulin glargine in combination with glimepiride in type 2 diabetes. Diabetic Medicine 2006; 23: 10
16. Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycaemic excursion with biphasic insulin aspart 30 injected immediately before a meal. Diabet Med 2004; 21: 500-501
17. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003; 17: 307-313
18. Liebl A et al. Poster presented at the American Diabetes Association (ADA), 2006. Abstract number 950876.
19. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes care 1999; 22: 801-805
20. McNally PG, Nelson G, Pitsch M. Patients with type 2 diabetes mellitus have lower rates of nocturnal hypoglycaemia on biphasic insulin aspart (BIAsp30) than on biphasic human insulin-30 (BH130): data from the REACH study. Diabetologia 2004; 47: A327
21. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265
22. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23: 583-588
23. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086
24. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000; 37: 41-46
25. Thivolet C, Clements M, Ligthelm RJ, Tits J, Kinsley B, Friberg HH. High-mix regimen of biphasic insulin aspart improves glycaemic control in patients with diabetes. Diabetologia 2002; 45: A254
26. Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients. Diabetes Res Clin Pract 2004; 66: 23-29
27. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20: 1612-1614
28. World Medical Association Declaration of Helsinki Ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043-3045